D2- and 5-HT2 receptor occupancy in high-dose neuroleptic-treated patients

International Journal of Neuropsychopharmacology

Volumn 1, Issue 2, 1998, Pages 95-101

  Nyberg, Svante ^a   Dencker, Sven Jonas ^b   Malm, Ulf ^b   Dahl, Marja Liisa ^a   Svenson, Jan Olof ^a   Halldin, Christer ^a   Naskashima, Yoshifumi ^c   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 HT2A receptor occupancy; D2 receptor occupancy; Fluphenazine; High dose treatment; Positron emission tomography; Schizophrenia

Indexed keywords

EID: 0002051542     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145798001229     Document Type: Article

References (32)

1. Andrée B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L (1998). Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. Journal of Clinical Pharmacology 18, 317-323.
2. Aubree JC, Lader MH (1980). High and very high dosage antipsychotics: A critical review. Journal of Clinical Psychiatry 41, 341-350.
3. Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79-91.
4. Barnes TRE (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
5. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980). Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences 7, 233.
6. Dahl M-L, Bertilsson L (1993). Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3, 61-70.
7. Dahl M-L, Ekqvist B, Widén J, Bertilsson L (1991). Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatrica Scandinavica 84, 99-100.
8. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F (1995). Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Journal of Pharmacology and Experimental Therapeutics 274, 516-520.
9. Dencker SJ, Enoksson P, Johansson R, Lundin L, Malm U (1981). Late (4-8 years) outcome of treatment with megadoses of fluphenazine enanthate in drug-refractory schizophrenics. Acta Psychiatrica Scandinavica 63, 1-12.
10. Dencker SJ, Johansson R, Lundin L, Malm U (1978). High doses of fluphenazine enanthate in schizophrenia. Acta Psychiatrica Scandinavica 57, 405-414.
11. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side-effects. Archives of General Psychiatry 49, 538-544.
12. Farde L, Wiesel F-A, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 45, 71-76.
13. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Psychiatry 47, 213-219.
14. Gerlach J (1991). New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin 17, 289-309.
15. Guy W (1976). Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology. ECDEU: National Institute of Health, pp. 218-222.
16. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O (1991). A comparative PET-study of five carbon-11 or fluorine-18 labeled salicylamides. Preparation and in vitro dopamine D-2 binding. International Journal of Radiation Applications & Instrumentation [B] 18, 871-881.
17. Heim M, Meyer U (1990). Genotyping of poor metabolizers of debrisosquin by allele-specific PCR amplification. Lancet 336, 529-532.
18. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the Natural Academy of Science USA 90, 11825-11829.
19. Kane JM, Marder SR (1993). Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin 19, 287-302.
20. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
21. Levinson DF, Simpson GM, Lo ES, Cooper TB, Singh H, Yadalam K, Stephanos MJ (1995). Fluphenazine plasma levels, dosage, efficacy, and side effects. American Journal of Psychiatry 152, 765-771.
22. 2 receptors. Psychopharmacology 112 (supplement.), S40-S54.
23. Meltzer HY (1991). The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin 17, 263-87.
24. Nordström A-L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry 152, 1444-1449.
25. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Human Psychopharmacology 7, 157-165.
26. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235.
27. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110, 265-272.
28. Nyberg S, Farde L, Halldin C (1997). PET study of 5HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16, 1-7.
29. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. American Journal of Psychiatry 152, 173-178.
30. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
31. Quitkin F, Rifkin A, Klein DF (1975). Very high dosage vs. standard dosage fluphenazine in schizophrenia. Archives of General Psychiatry 32, 1276-1271.
32. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiuhe C-Y, Cooper TB, Brodie JD (1989). Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry 146, 905-908.